By 48 weeks, significant average weight loss was seen at all maintenance doses: With longer treatment lasting up to 68 weeks, weight loss continued, particularly at higher doses: 12mg: average weight loss of up to 28.7% of body weight This longer-term data shows that weight loss with retatrutide can continue beyond one year, rather than plateauing early, especially at higher maintenance doses
The potential clinical applications of magnetothermal neuromodulation are extensive, offering hope for non-invasive treatments for a variety of neurological and psychiatric disorders
In this state, the peptide can survive months or even years at controlled temperatures without degrading
The NHS side-effects guidance for hydroxocobalamin, the form used in the UK, lists nausea, headache, dizziness and injection-site reactions as known effects that usually pass on their own